Exome Asset Management »

Maze Therapeatics shares owned by Exome Asset Management

Quarter-by-quarter ownership of Maze Therapeatics (MAZE) shares owned by Exome Asset Management from 13F filings

Historical chart of Exome Asset Management investment in Maze Therapeatics

Tip: Access up to 7 years of quarterly data

All positions including Maze Therapeatics held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Maze Therapeatics by Exome Asset Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $2.6M 89k 29.85

More positions owned by Exome Asset Management

Praxis Precision Medicines I Com New (PRAX)
Cogent Biosciences (COGT)
Enliven Therapeutics (ELVN)
Ionis Pharmaceuticals (IONS)
Spdr Series Trust State Street Spd Put Option (XBI)
Guardant Health (GH)
Cytokinetics Com New (CYTK)
Eli Lilly & Co. (LLY)
Alumis (ALMS)
Bridgebio Pharma (BBIO)
Vera Therapeutics Cl A (VERA)
Insmed Com Par $.01 (INSM)
Anthem (ELV)
Agios Pharmaceuticals (AGIO)
United Therapeutics Corporation (UTHR)

View all positions for Exome Asset Management

Top funds holding Maze Therapeatics

Frazier Life Sciences Management
Trv Gp Iv
Arch Venture Corp
Deep Track Capital
Henderson Group
Paradigm Biocapital Advisors
BlackRock
AH Capital Management
VR Adviser
Vanguard Capital Management
Alphabet
Logos Global Management
Adage Capital Partners GP
General Catalyst Group Management
TRV GP V

View all funds holding Maze Therapeatics